FLT3 Inhibitors in AML: Are We There Yet?
- 30 March 2014
- journal article
- research article
- Published by Springer Nature in Current Hematologic Malignancy Reports
- Vol. 9 (2) , 174-185
Abstract
FMS-like tyrosine kinase 3 (FLT3) is the most frequently mutated gene in AML. Thirty percent of patients with acute myeloid leukemia (AML) harbor activating mutations in FLT3, either internal tandem duplication mutations in the juxtamembrane domain (FLT3-ITD) or point mutations in the tyrosine kinase domain (FLT3 TKD). Small molecule FLT3 inhibitors have emerged as an attractive therapeutic option in patients with FLT3 mutations; however, the clinical activity of early inhibitors was limited by a lack of selectivity, potency and unfavorable pharmacokinetic properties. Newer agents such as quizartinib have improved potency and selectivity associated with much higher bone marrow response rates; however, response duration is limited by the development of secondary resistance. We will review here a number of FLT3 inhibitors that have been evaluated in clinical trials and discuss challenges facing the use of these agents in AML.Keywords
This publication has 75 references indexed in Scilit:
- Genomic and Epigenomic Landscapes of Adult De Novo Acute Myeloid LeukemiaNew England Journal of Medicine, 2013
- The Origin and Evolution of Mutations in Acute Myeloid LeukemiaCell, 2012
- Validation of ITD mutations in FLT3 as a therapeutic target in human acute myeloid leukaemiaNature, 2012
- Role of Allogeneic Transplantation for FLT3/ITD Acute Myeloid Leukemia: Outcomes from 133 Consecutive Newly Diagnosed Patients from a Single InstitutionTransplantation and Cellular Therapy, 2011
- A pharmacodynamic study of sorafenib in patients with relapsed and refractory acute leukemiasLeukemia, 2010
- A Robust Error Model for iTRAQ Quantification Reveals Divergent Signaling between Oncogenic FLT3 Mutants in Acute Myeloid LeukemiaMolecular & Cellular Proteomics, 2010
- A pharmacodynamic study of the FLT3 inhibitor KW-2449 yields insight into the basis for clinical responseBlood, 2009
- Knock-in of an internal tandem duplication mutation into murine FLT3 confers myeloproliferative disease in a mouse modelBlood, 2008
- Phase 1 clinical results with tandutinib (MLN518), a novel FLT3 antagonist, in patients with acute myelogenous leukemia or high-risk myelodysplastic syndrome: safety, pharmacokinetics, and pharmacodynamicsBlood, 2006
- Roles of tyrosine 589 and 591 in STAT5 activation and transformation mediated by FLT3-ITDBlood, 2006